Period,symbol,NAV,sharesOutstanding,researchDevelopment,effectOfAccountingCharges,incomeBeforeTax,minorityInterest,netIncome,sellingGeneralAdministrative,grossProfit,ebit,operatingIncome,otherOperatingExpenses,interestExpense,extraordinaryItems,nonRecurring,otherItems,incomeTaxExpense,totalRevenue,totalOperatingExpenses,costOfRevenue,totalOtherIncomeExpenseNet,discontinuedOperations,netIncomeFromContinuingOps,netIncomeApplicableToCommonShares,intangibleAssets,capitalSurplus,totalLiab,totalStockholderEquity,otherCurrentLiab,totalAssets,commonStock,otherCurrentAssets,retainedEarnings,otherLiab,goodWill,treasuryStock,otherAssets,cash,totalCurrentLiabilities,deferredLongTermAssetCharges,shortLongTermDebt,otherStockholderEquity,propertyPlantEquipment,totalCurrentAssets,longTermInvestments,shortTermInvestments,netReceivables,longTermDebt,inventory,accountsPayable,investments,changeToLiabilities,totalCashflowsFromInvestingActivities,netBorrowings,totalCashFromFinancingActivities,changeToOperatingActivities,changeInCash,effectOfExchangeRate,totalCashFromOperatingActivities,depreciation,otherCashflowsFromInvestingActivities,dividendsPaid,otherCashflowsFromFinancingActivities,changeToNetincome,capitalExpenditures,changeToInventory,changeToAccountReceivables,WC,language,region,quoteType,triggerable,quoteSourceName,currency,priceHint,exchange,regularMarketPrice,regularMarketTime,regularMarketChange,regularMarketOpen,regularMarketDayHigh,regularMarketDayLow,regularMarketVolume,exchangeDataDelayedBy,shortName,marketState,market,regularMarketChangePercent,regularMarketDayRange,regularMarketPreviousClose,bid,ask,bidSize,askSize,messageBoardId,fullExchangeName,longName,financialCurrency,averageDailyVolume3Month,averageDailyVolume10Day,fiftyTwoWeekLowChange,fiftyTwoWeekLowChangePercent,fiftyTwoWeekRange,fiftyTwoWeekHighChange,fiftyTwoWeekHighChangePercent,fiftyTwoWeekLow,fiftyTwoWeekHigh,earningsTimestamp,earningsTimestampStart,earningsTimestampEnd,trailingAnnualDividendRate,trailingPE,trailingAnnualDividendYield,fiftyDayAverageChangePercent,twoHundredDayAverage,twoHundredDayAverageChange,twoHundredDayAverageChangePercent,forwardPE,epsTrailingTwelveMonths,epsForward,bookValue,fiftyDayAverage,fiftyDayAverageChange,marketCap,priceToBook,sourceInterval,exchangeTimezoneName,exchangeTimezoneShortName,gmtOffSetMilliseconds,esgPopulated,tradeable,Beta (5Y Monthly),52-Week Change 3,S&P500 52-Week Change 3,52 Week High 3,52 Week Low 3,50-Day Moving Average 3,200-Day Moving Average 3,Avg Vol (3 month) 3,Avg Vol (10 day) 3,Shares Outstanding 5,Implied Shares Outstanding 6,Float,% Held by Insiders 1,% Held by Institutions 1,Shares Short 4,Short Ratio 4,Short % of Float 4,Short % of Shares Outstanding 4,Shares Short (prior month ) 4,Forward Annual Dividend Rate 4,Forward Annual Dividend Yield 4,Trailing Annual Dividend Rate 3,Trailing Annual Dividend Yield 3,5 Year Average Dividend Yield 4,Payout Ratio 4,Dividend Date 3,Ex-Dividend Date 4,Last Split Factor 2,Last Split Date 3,Fiscal Year Ends,Most Recent Quarter (mrq),Profit Margin,Operating Margin (ttm),Return on Assets (ttm),Return on Equity (ttm),Revenue (ttm),Revenue Per Share (ttm),Quarterly Revenue Growth (yoy),Gross Profit (ttm),EBITDA,Net Income Avi to Common (ttm),Diluted EPS (ttm),Quarterly Earnings Growth (yoy),Total Cash (mrq),Total Cash Per Share (mrq),Total Debt (mrq),Total Debt/Equity (mrq),Current Ratio (mrq),Book Value Per Share (mrq),Operating Cash Flow (ttm),Levered Free Cash Flow (ttm),index,zip,sector,fullTimeEmployees,compensationRisk,auditRisk,longBusinessSummary,city,phone,state,shareHolderRightsRisk,compensationAsOfEpochDate,governanceEpochDate,boardRisk,country,website,maxAge,overallRisk,address1,industry
t0,LLY.DE,-5066500000,959025024,1684800000,,1476400000,200600000,1355300000,1502600000,4927000000,1739600000,1739600000,,-87800000,,,,121100000,6805600000,5066000000,1878600000,-263200000,,1355300000,1355300000,8087800000,6579200000,39739000000,6898700000,3552900000,46838300000,599700000,14800000,9181300000,11779400000,3877400000,-9461500000,6041100000,3002400000,11714200000,2649900000,50400000,-9408800000,8630100000,16604500000,3597400000,49000000,6631100000,16245400000,3660800000,1639600000,-22100000.0,0.0,-1283500000.0,-3700000.0,-1058400000.0,-102800000.0,-654700000.0,-10200000.0,1697400000.0,350300000.0,-21900000.0,-774800000.0,-279900000.0,94600000.0,-300300000.0,,,4890300000,en-US,US,EQUITY,False,Delayed Quote,EUR,2,GER,217.5,1630578039,0.69999695,216.3,217.5,216.3,206,0,ELI LILLY,REGULAR,de_market,0.3228768,216.3 - 217.5,216.8,216.7,217.5,0,0,finmb_285467,XETRA,Eli Lilly and Company,USD,963,442,106.62,0.96158016,110.88 - 234.8,-17.300003,-0.07367974,110.88,234.8,1635251400,1635251400,1635251400,3.07,38.867046,0.014160516,0.0029842379,180.5943,36.9057,0.20435695,36.61616,5.596,5.94,7.589,216.85286,0.6471405,212412022784,28.659903,15,Europe/Berlin,CEST,7200000,False,False,0.24,,,234.8,110.88,216.85,180.59,963,442,959.03M,,857.1M,0.15%,83.64%,,,,,,2.79,1.49%,3.07,1.42%,,45.96%,,"May 13, 2021",,,"Dec 31, 2020","Mar 31, 2021",23.91%,27.83%,10.08%,118.34%,25.49B,28.08,16.10%,19.06B,8.49B,6.09B,5.60,-6.90%,3.06B,3.37,16.3B,229.54,1.42,7.59,7.81B,4.65B,Value,46285,Healthcare,34690,4,4,"Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceuticals worldwide. It offers Baqsimi for severe hypoglycemia; Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500, and Lyumjev for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company also provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+ and HER2- metastatic breast cancer. In addition, it offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. Further, the company Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; Reyvow for migraine; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Additionally, it Bamlanivimab and etesevimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. Eli Lilly and Company has collaborations with Incyte Corporation; Pfizer Inc.; AC Immune SA; Centrexion Therapeutics Corporation; ImmuNext, Inc.; Avidity Biosciences, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; and MiNA Therapeutics Limited. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.",Indianapolis,317 276 2000,IN,9,1609372800,1622505600,10,United States,http://www.lilly.com,86400,8,Lilly Corporate Center,Drug Manufacturers—General
t-1,LLY.DE,-5574900000,959025024,1838000000,,2469100000,183600000,2116800000,1496600000,5720200000,2385600000,2385600000,,-89200000,,,,352300000,7440000000,5054400000,1719800000,83500000,,2116800000,2116800000,7450000000,6778500000,40807900000,5641600000,3697200000,46633100000,598200000,41100000,7830200000,11029000000,3766500000,-9565300000,6074400000,3657100000,12481600000,2830400000,101300000,-9509600000,8681900000,17462100000,3198200000,24200000,6887900000,16784500000,3980300000,1606700000,58900000.0,1271300000.0,-674100000.0,-580100000.0,-1291500000.0,-224900000.0,61800000.0,212200000.0,1815200000.0,367500000.0,86500000.0,-670000000.0,-41400000.0,-153900000.0,-454700000.0,-533400000.0,-1350200000.0,4980500000,en-US,US,EQUITY,False,Delayed Quote,EUR,2,GER,217.5,1630578039,0.69999695,216.3,217.5,216.3,206,0,ELI LILLY,REGULAR,de_market,0.3228768,216.3 - 217.5,216.8,216.7,217.5,0,0,finmb_285467,XETRA,Eli Lilly and Company,USD,963,442,106.62,0.96158016,110.88 - 234.8,-17.300003,-0.07367974,110.88,234.8,1635251400,1635251400,1635251400,3.07,38.867046,0.014160516,0.0029842379,180.5943,36.9057,0.20435695,36.61616,5.596,5.94,7.589,216.85286,0.6471405,212412022784,28.659903,15,Europe/Berlin,CEST,7200000,False,False,0.24,,,234.8,110.88,216.85,180.59,963,442,959.03M,,857.1M,0.15%,83.64%,,,,,,2.79,1.49%,3.07,1.42%,,45.96%,,"May 13, 2021",,,"Dec 31, 2020","Mar 31, 2021",23.91%,27.83%,10.08%,118.34%,25.49B,28.08,16.10%,19.06B,8.49B,6.09B,5.60,-6.90%,3.06B,3.37,16.3B,229.54,1.42,7.59,7.81B,4.65B,Value,46285,Healthcare,34690,4,4,"Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceuticals worldwide. It offers Baqsimi for severe hypoglycemia; Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500, and Lyumjev for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company also provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+ and HER2- metastatic breast cancer. In addition, it offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. Further, the company Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; Reyvow for migraine; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Additionally, it Bamlanivimab and etesevimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. Eli Lilly and Company has collaborations with Incyte Corporation; Pfizer Inc.; AC Immune SA; Centrexion Therapeutics Corporation; ImmuNext, Inc.; Avidity Biosciences, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; and MiNA Therapeutics Limited. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.",Indianapolis,317 276 2000,IN,9,1609372800,1622505600,10,United States,http://www.lilly.com,86400,8,Lilly Corporate Center,Drug Manufacturers—General
t-2,LLY.DE,-6488100000,959025024,1465400000,,1437200000,169100000,1208400000,1455100000,4414200000,1493700000,1493700000,,-89600000,,,,228800000,5740600000,4246900000,1326400000,-56500000,,1208400000,1208400000,7588600000,6698800000,38950000000,4826900000,3388200000,43946000000,598100000,8500000,7154000000,10366700000,3726400000,-9624000000,5390700000,3595300000,11976900000,2555300000,37900000,-9568300000,8281100000,16239900000,2719300000,35000000,5834100000,16606400000,3555400000,1430100000,89400000.0,0.0,-313500000.0,394800000.0,-279100000.0,249400000.0,1230200000.0,16200000.0,1806600000.0,358400000.0,12200000.0,-671600000.0,-2300000.0,-9600000.0,-393100000.0,-533400000.0,-1350200000.0,4263000000,en-US,US,EQUITY,False,Delayed Quote,EUR,2,GER,217.5,1630578039,0.69999695,216.3,217.5,216.3,206,0,ELI LILLY,REGULAR,de_market,0.3228768,216.3 - 217.5,216.8,216.7,217.5,0,0,finmb_285467,XETRA,Eli Lilly and Company,USD,963,442,106.62,0.96158016,110.88 - 234.8,-17.300003,-0.07367974,110.88,234.8,1635251400,1635251400,1635251400,3.07,38.867046,0.014160516,0.0029842379,180.5943,36.9057,0.20435695,36.61616,5.596,5.94,7.589,216.85286,0.6471405,212412022784,28.659903,15,Europe/Berlin,CEST,7200000,False,False,0.24,,,234.8,110.88,216.85,180.59,963,442,959.03M,,857.1M,0.15%,83.64%,,,,,,2.79,1.49%,3.07,1.42%,,45.96%,,"May 13, 2021",,,"Dec 31, 2020","Mar 31, 2021",23.91%,27.83%,10.08%,118.34%,25.49B,28.08,16.10%,19.06B,8.49B,6.09B,5.60,-6.90%,3.06B,3.37,16.3B,229.54,1.42,7.59,7.81B,4.65B,Value,46285,Healthcare,34690,4,4,"Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceuticals worldwide. It offers Baqsimi for severe hypoglycemia; Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500, and Lyumjev for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company also provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+ and HER2- metastatic breast cancer. In addition, it offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. Further, the company Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; Reyvow for migraine; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Additionally, it Bamlanivimab and etesevimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. Eli Lilly and Company has collaborations with Incyte Corporation; Pfizer Inc.; AC Immune SA; Centrexion Therapeutics Corporation; ImmuNext, Inc.; Avidity Biosciences, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; and MiNA Therapeutics Limited. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.",Indianapolis,317 276 2000,IN,9,1609372800,1622505600,10,United States,http://www.lilly.com,86400,8,Lilly Corporate Center,Drug Manufacturers—General
t-3,LLY.DE,-7342800000,959025024,1390200000,,1643700000,179100000,1412000000,1412700000,4277400000,1474500000,1474500000,,-88300000,,,,231700000,5499400000,4024900000,1222000000,169200000,,1412000000,1412000000,7712500000,6629400000,37695000000,4092900000,3514600000,41967000000,598100000,3700000,6617200000,10287900000,3723200000,-9751800000,5273600000,2365100000,11988500000,2481800000,12100000,-9696100000,7981100000,14581900000,2694700000,22800000,5770700000,15418600000,3313900000,1247200000,360100000.0,0.0,-210400000.0,-995500000.0,-1673200000.0,926500000.0,666100000.0,54300000.0,2495400000.0,324400000.0,-47300000.0,-674200000.0,-3500000.0,-167500000.0,-281800000.0,-533400000.0,-1350200000.0,2593400000,en-US,US,EQUITY,False,Delayed Quote,EUR,2,GER,217.5,1630578039,0.69999695,216.3,217.5,216.3,206,0,ELI LILLY,REGULAR,de_market,0.3228768,216.3 - 217.5,216.8,216.7,217.5,0,0,finmb_285467,XETRA,Eli Lilly and Company,USD,963,442,106.62,0.96158016,110.88 - 234.8,-17.300003,-0.07367974,110.88,234.8,1635251400,1635251400,1635251400,3.07,38.867046,0.014160516,0.0029842379,180.5943,36.9057,0.20435695,36.61616,5.596,5.94,7.589,216.85286,0.6471405,212412022784,28.659903,15,Europe/Berlin,CEST,7200000,False,False,0.24,,,234.8,110.88,216.85,180.59,963,442,959.03M,,857.1M,0.15%,83.64%,,,,,,2.79,1.49%,3.07,1.42%,,45.96%,,"May 13, 2021",,,"Dec 31, 2020","Mar 31, 2021",23.91%,27.83%,10.08%,118.34%,25.49B,28.08,16.10%,19.06B,8.49B,6.09B,5.60,-6.90%,3.06B,3.37,16.3B,229.54,1.42,7.59,7.81B,4.65B,Value,46285,Healthcare,34690,4,4,"Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceuticals worldwide. It offers Baqsimi for severe hypoglycemia; Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500, and Lyumjev for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company also provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+ and HER2- metastatic breast cancer. In addition, it offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. Further, the company Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; Reyvow for migraine; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Additionally, it Bamlanivimab and etesevimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. Eli Lilly and Company has collaborations with Incyte Corporation; Pfizer Inc.; AC Immune SA; Centrexion Therapeutics Corporation; ImmuNext, Inc.; Avidity Biosciences, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; and MiNA Therapeutics Limited. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.",Indianapolis,317 276 2000,IN,9,1609372800,1622505600,10,United States,http://www.lilly.com,86400,8,Lilly Corporate Center,Drug Manufacturers—General
